文献速递头颈部肿瘤放疗

局部激素预防头颈癌放化疗放射性皮炎的3期随机试验

Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-06-06

这项3期多中心随机双盲安慰剂对照试验纳入211例接受双侧颈部放疗(≥66 Gy)同步顺铂(≥200 mg/m²)的头颈癌患者,评估局部激素预防放射性皮炎的疗效与安全性。结果显示局部激素未显著降低≥2级放射性皮炎发生率(73.3% vs 80.4%,P=.23),但显著降低≥3级发生率(13.9% vs 25.5%,P=.034),不良事件无显著差异。

要点

  • 局部激素未显著减少≥2级放射性皮炎,但显著降低≥3级发生率。
  • 两组不良事件包括局部感染及放化疗依从性无显著差异。
  • 局部激素可能减轻头颈癌放化疗放射性皮炎严重程度。

核心结论

  • 局部激素可能减轻头颈癌患者放化疗所致放射性皮炎的严重程度。
  • 局部激素未显著降低≥2级放射性皮炎发生率,但显著降低≥3级发生率。

研究设计与样本

  • 3期多中心随机双盲安慰剂对照试验,纳入211例局部晚期头颈癌接受根治性或术后放化疗患者。
  • 患者计划接受双侧颈部放疗(≥66 Gy)同步顺铂(≥200 mg/m²)。
  • 出现1级放射性皮炎或总放疗剂量达30 Gy时随机分配至局部激素组或安慰剂组,两组均行基础皮肤护理。
  • 主要终点为根据NCI CTCAE v4.0标准≥2级放射性皮炎的发生率,由独立中心审查每周照片进行分级。

主要发现

  • 意向治疗人群为激素组101例、安慰剂组102例。
  • ≥2级放射性皮炎发生率激素组73.3%(95%CI 64.6%-81.9%),安慰剂组80.4%(95%CI 72.7%-88.1%),P=.23。
  • ≥3级放射性皮炎发生率激素组13.9%,安慰剂组25.5%,P=.034。
  • 两组不良事件包括局部感染或放化疗依从性无显著差异。

关键数值与推荐

  • 主要终点≥2级放射性皮炎发生率组间差异无统计学意义(P=.23)。
  • ≥3级放射性皮炎发生率激素组显著低于安慰剂组(13.9% vs 25.5%,P=.034)。

临床怎么用

  • 对于接受双侧颈部放疗(≥66 Gy)同步顺铂(≥200 mg/m²)的头颈癌患者,局部激素可考虑用于降低≥3级放射性皮炎的发生率。
  • 使用局部激素时需结合基础皮肤护理,并监测局部感染等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation dermatitis is one of the most common acute toxicities induced by chemoradiation therapy (CRT) for head and neck cancer (HNC). The benefit of topical steroids in the management of radiation dermatitis is still unclear. This phase 3, multi-institutional, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of topical steroids for radiation dermatitis in patients with locally advanced HNC receiving CRT. METHODS AND MATERIALS: Eligible patients were scheduled to receive bilateral neck irradiation (≥66 Gy) with concurrent cisplatin (≥200 mg/m2) as definitive or postoperative CRT. Patients were randomly assigned to receive either topical steroid or placebo when grade 1radiation dermatitis was observed or the total radiation dose reached 30 Gy. Basic skin care including gentle washing and moistening in the head and neck region was performed in both groups. The primary endpoint was the frequency of grade ≥2 radiation dermatitis, in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Grading of radiation dermatitis was performed by independent central review using photographs taken weekly. RESULTS: A total of 211 patients were enrolled (intention to treat: steroid 101 and placebo 102). The frequency of grade ≥2 radiation dermatitis was not significantly reduced with the steroid (73.3%; 95% confidence interval, 64.6%-81.9%) compared with the placebo (80.4%; 95% confidence interval, 72.7%-88.1%; P = .23), whereas the steroid significantly reduced the frequency of grade ≥3 radiation dermatitis (13.9% vs 25.5%; P = .034). No significant differences in adverse events, including local infection or compliance with CRT, were observed between the groups. CONCLUSIONS: Topical steroid may reduce the severity of radiation dermatitis in patients with HNC and thus may become an important therapeutic tool in the management of radiation dermatitis.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yokota T, Zenda S, Ota I, et al. Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation. Int J Radiat Oncol Biol Phys. 2021. PMID: 34102298. doi:10.1016/j.ijrobp.2021.05.133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。